{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:13:45Z","timestamp":1790723625676,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81873758"],"award-info":[{"award-number":["81873758"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.jneuroim.2021.577569","type":"journal-article","created":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T11:55:26Z","timestamp":1617796526000},"page":"577569","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Tacrolimus as a therapeutic option in patients with acquired neuromyotonia"],"prefix":"10.1016","volume":"355","author":[{"given":"Chenchen","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suqiong","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuajin","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huajie","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bitao","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2021.577569_bb0005","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/mus.24632","article-title":"Isaacs syndrome: a review","volume":"52","author":"Ahmed","year":"2015","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2021.577569_bb0010","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/jnnp-2017-315720","article-title":"LGI1, CASPR2 and related antibodies: a molecular evolution of the phenotypes","volume":"89","author":"Binks","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2021.577569_bb0015","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41584-020-0374-8","article-title":"Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology","volume":"16","author":"Broen","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.jneuroim.2021.577569_bb0020","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/s41598-017-00860-y","article-title":"Efficacy and safety of tacrolimus treatment for neuromyelitis optica spectrum disorder","volume":"7","author":"Chen","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jneuroim.2021.577569_bb0025","first-page":"740","article-title":"Tacrolimus combined with corticosteroids effectively improved the outcome of a cohort of patients with immune-mediated necrotising myopathy","volume":"37","author":"Feng","year":"2019","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jneuroim.2021.577569_bb0030","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1212\/WNL.0000000000003887","article-title":"Clinical manifestations of the anti-IgLON5 disease","volume":"88","author":"Gaig","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2021.577569_bb0035","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000393","article-title":"Understanding anti-IgLON5 disease","volume":"4","author":"Graus","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jneuroim.2021.577569_bb0040","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1093\/brain\/awf178","article-title":"Phenotypic variants of autoimmune peripheral nerve hyperexcitability","volume":"125","author":"Hart","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.jneuroim.2021.577569_bb0045","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000385","article-title":"IgLON5 antibody: neurological accompaniments and outcomes in 20 patients","volume":"4","author":"Honorat","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jneuroim.2021.577569_bb0050","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/jca.21233","article-title":"Plasma exchange as a therapeutic option in patients with neurologic symptoms due to antibodies to voltage-gated potassium channels: a report of five cases and review of the literature","volume":"27","author":"Jaben","year":"2012","journal-title":"J. Clin. Apher."},{"key":"10.1016\/j.jneuroim.2021.577569_bb0055","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1136\/jnnp.2004.042176","article-title":"Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus)","volume":"76","author":"Konishi","year":"2005","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2021.577569_bb0060","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1016\/j.clinph.2006.03.008","article-title":"Neuromyotonia","volume":"117","author":"Maddison","year":"2006","journal-title":"Clin. Neurophysiol."},{"key":"10.1016\/j.jneuroim.2021.577569_bb0065","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s10067-012-2044-y","article-title":"Effects of tacrolimus on dermatomyositis and polymyositis: a prospective, open, non-randomized study of nine patients and a review of the literature","volume":"31","author":"Matsubara","year":"2012","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.jneuroim.2021.577569_bb0070","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1093\/brain\/awh605","article-title":"The wide spectrum of clinical manifestations in Sjogren\u2019s syndrome-associated neuropathy","volume":"128","author":"Mori","year":"2005","journal-title":"Brain."},{"key":"10.1016\/j.jneuroim.2021.577569_bb0075","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1136\/jnnp-2020-324675","article-title":"Isaacs syndrome: the frontier of neurology, psychiatry, immunology and cancer","volume":"91","author":"Park","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2021.577569_bb0080","doi-asserted-by":"crossref","first-page":"99","DOI":"10.5114\/reum.2018.75521","article-title":"Neurological manifestations of primary Sjogren\u2019s syndrome","volume":"56","author":"Perzynska-Mazan","year":"2018","journal-title":"Reumatologia"},{"key":"10.1016\/j.jneuroim.2021.577569_bb0085","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/mus.20543","article-title":"Mycophenolate mofetil and tacrolimus: new therapeutic options in neuroimmunological diseases","volume":"34","author":"Schneider-Gold","year":"2006","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2021.577569_bb0090","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/ana.410380505","article-title":"Acquired neuromyotonia: evidence for autoantibodies directed against K+ channels of peripheral nerves","volume":"38","author":"Shillito","year":"1995","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577569_bb0095","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jocn.2017.02.063","article-title":"Isaacs syndrome with CASPR2 antibody: a series of three cases","volume":"41","author":"Song","year":"2017","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.jneuroim.2021.577569_bb0100","first-page":"757","article-title":"Isaacs\u2019 syndrome (autoimmune neuromyotonia) in a patient with systemic lupus erythematosus","volume":"32","author":"Taylor","year":"2005","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jneuroim.2021.577569_bb0105","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1001\/jamaneurol.2018.2681","article-title":"Association of leucine-rich glioma inactivated protein 1, contactin-associated protein 2, and contactin 2 antibodies with clinical features and patient-reported pain in acquired neuromyotonia","volume":"75","author":"Vincent","year":"2018","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jneuroim.2021.577569_bb0110","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3233\/JND-170259","article-title":"Expanding the clinical spectrum of IgLON5-syndrome","volume":"4","author":"Wenninger","year":"2017","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.jneuroim.2021.577569_bb0115","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s10067-016-3499-z","article-title":"Neuromyotonia as an unusual neurological complication of primary Sjogren\u2019s syndrome: case report and literature review","volume":"36","author":"Xiao","year":"2017","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.jneuroim.2021.577569_bb0120","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s13760-020-01446-8","article-title":"Effectiveness of immunotherapy in a CASPR2 and LGI1 antibody-positive elderly patient with Isaacs\u2019 syndrome: a case study","volume":"121","author":"Ye","year":"2020","journal-title":"Acta Neurol. Belg."},{"key":"10.1016\/j.jneuroim.2021.577569_bb0125","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1093\/rheumatology\/keh155","article-title":"Safety of tacrolimus in patients with rheumatoid arthritis: long-term experience","volume":"43","author":"Yocum","year":"2004","journal-title":"Rheumatology (Oxford)"}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572821000965?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572821000965?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:38:45Z","timestamp":1759048725000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572821000965"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":25,"alternative-id":["S0165572821000965"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2021.577569","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tacrolimus as a therapeutic option in patients with acquired neuromyotonia","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2021.577569","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"577569"}}